We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+25.75%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.5B
AUM Growth
+$474M
(+16%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
4.97%
Top 10 Holdings %
Top 10 Hldgs %
60.94%
Holding
54
New
11
Increased
8
Reduced
10
Closed
5
Top Buys
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$94.1M |
| 2 |
Disc Medicine
IRON
|
+$93.1M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$85.6M |
| 4 |
Vor Biopharma
VOR
|
+$80M |
| 5 |
Immunovant
IMVT
|
+$72.4M |
Top Sells
| 1 |
RAPT
RAPT Therapeutics
RAPT
|
+$87.5M |
| 2 |
ABVX
Abivax
ABVX
|
+$74.6M |
| 3 |
EyePoint Inc
EYPT
|
+$65.3M |
| 4 |
Structure Therapeutics
GPCR
|
+$53.4M |
| 5 |
Liquidia Corp
LQDA
|
+$48.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Century Therapeutics
IPSC
$408M
| $39M | 1.12% |
+17,754,430
| New | +$37.3M |
|
|
TECX
27
Tectonic Therapeutic
TECX
$578M
| $37.2M | 1.07% |
+1,204,891
| New | +$29.7M |
|
28
Perspective Therapeutics
CATX
$336M
| $33M | 0.94% |
+7,915,567
| New | +$33.4M |
|
29
Xencor
XNCR
$1.11B
| $29.6M | 0.85% |
2,452,138
| – | – |
|
30
Entrada Therapeutics
TRDA
$267M
| $28.9M | 0.83% |
2,287,500
+199,108
| +10% | +$2.28M |
|
31
ALX Oncology
ALXO
$279M
| $26.1M | 0.75% |
+13,011,849
| New | +$24.8M |
|
32
Arvinas
ARVN
$518M
| $25.3M | 0.72% |
2,387,461
-278,755
| -10% | -$3.45M |
|
33
Janux Therapeutics
JANX
$966M
| $24.9M | 0.71% |
1,789,617
| – | – |
|
|
AGMB
34
AgomAb Therapeutics NV
AGMB
$607M
| $21.5M | 0.62% |
+2,053,233
| New | +$29.1M |
|
35
Alector
ALEC
$163M
| $21.5M | 0.62% |
10,000,000
| – | – |
|
|
MBX
36
MBX Biosciences
MBX
$2.78B
| $19.4M | 0.56% |
650,000
| – | – |
|
|
SLN
37
Silence Therapeutics
SLN
$516M
| $16M | 0.46% |
3,033,560
| – | – |
|
|
38
Liquidia Corp
LQDA
$6.69B
| $15.2M | 0.44% |
403,048
-1,307,036
| -76% | -$48.5M |
|
39
Ocular Therapeutix
OCUL
$2.01B
| $14M | 0.4% |
1,647,752
-4,092,479
| -71% | -$39M |
|
40
Avalo Therapeutics
AVTX
$940M
| $11M | 0.32% |
738,383
+255,383
| +53% | +$3.99M |
|
41
UroGen Pharma
URGN
$1.95B
| $7.29M | 0.21% |
405,365
-311,982
| -43% | -$6.25M |
|
42
Monopar Therapeutics
MNPR
$727M
| $7.24M | 0.21% |
132,103
-9,812
| -7% | -$593K |
|
43
Context Therapeutics
CNTX
$56.5M
| $7.03M | 0.2% |
+2,682,696
| New | +$6.26M |
|
|
44
Structure Therapeutics
GPCR
$3.27B
| $6.77M | 0.19% |
140,411
-780,446
| -85% | -$53.4M |
|
45
Cullinan Oncology
CGEM
$1.01B
| $5.78M | 0.17% |
+406,786
| New | +$5.23M |
|
46
Korro Bio
KRRO
$177M
| $4.71M | 0.13% |
416,301
| – | – |
|
|
LONA
47
LeonaBio Inc
LONA
$73.4M
| $4.67M | 0.13% |
464,398
| – | – |
|
|
UPB
48
Upstream Bio Inc
UPB
$393M
| $1.63M | 0.05% |
181,063
-562,823
| -76% | -$10.1M |
|
49
VistaGen Therapeutics
VTGN
$9.85M
| $1.53M | 0.04% |
2,676,580
| – | – |
|
50
Agios Pharmaceuticals
AGIO
$2.3B
| – | – |
-1,181,841
| Closed | -$32.2M |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC